Saha S, et al. - Researchers conducted an open label randomized-controlled-trial with the aim to determine the effect of alfacalcidol vs calcitriol on phosphatemic control, hypercalciuria and associated factors in idiopathic-hypoparathyroidism (IH). IH patients with optimal calcemic control on alfacalcidol were continued to receive the same (n = 20) or were switched to calcitriol (n = 25) at half of the ongoing alfacalcidol dose. Adjustment of the dose was done during follow-up to maintain serum total calcium between 8.0-9.5 mg/dL. Findings suggest that at optimal calcium control, both alfacalcidol and calcitriol results in comparable but high serum phosphate levels, hypercalciuria, physiological circulating 1,25(OH)2D and elevated FGF23.